Advances in FDA's Drug Safety Programs
Drug Safety is a Key Priority at the Center for Drug Evaluation and Research
Drug Safety Priorities FY 2024
(PDF - 1.8 MB)
Drug Safety is a Key Priority at the Center for Drug Evaluation and Research
CDER Drug Safety Priorities Fiscal Year 2024 is the tenth yearly report describing key safety drug operations and illustrating broad safety initiatives across the Center and FDA. The report features CDER’s advancements to promote and protect public health, including ongoing activities to address the national drug overdose crisis. These efforts include launching a campaign to help health care professionals recognize and treat opioid use disorder. The report also details the Center’s work to prevent medication shortages and communicate about recalls and related safety information to the public. Links to previous CDER Drug Safety Priorities reports are available below.
Prior Drug Safety Priorities Reports
- Drug Safety Priorities 2023 (PDF - 3 MB)
- Drug Safety Priorities 2022 (PDF - 4 MB)
- Drug Safety Priorities 2021 (PDF - 10 MB)
- Drug Safety Priorities 2020 (PDF - 7 MB)
- Drug Safety Priorities 2019 (PDF - 908 KB)
- Drug Safety Priorities 2018 (PDF - 12 MB)